u/chidi_demir

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

private pricing varies enormously between neighbouring countries

MASH endpoints are histological, which is a much harder bar

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

the lane is the unit of analysis, not the supplier

Not convinced by four data points. That is not a lane yet, it is an anecdote with a route attached.

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

How many shipments does your figure cover?

The variation between pharmacies inside my own country was larger than the variation I had been chasing across the border.

Not quite. Two labs with different gradients can resolve a close-eluting impurity differently and both be reporting honestly.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Ordered from the warehouse in New Zealand instead of origin and the whole customs question disappeared.

Adding the field everyone forgets — the month. Without it the report is not comparable to anything.

MASH endpoints are histological, which is a much harder bar

Push back: the evidence here is phase 2, in a specific population, and it does not support a general ranking.

Careful.

Agreed — and the follow-up question is what the beyond-use date is based on.

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

no tracking numbers, ever

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

a total of 0.4% tells you less than four named impurities adding to 0.6%

the language barrier is a real cost and nobody budgets for it

How long after a step up did this start?

Ask what the stability statement was written against — temperature, light, and whether it was the lyophilised powder or the reconstituted solution. Those are three different claims.

staying at 0.25mg for an extra month is a legitimate plan

ask for the storage condition the stability statement was written against

What was the packaging like on arrival?

Origin, destination, carrier and month?

Asked ERP which lines they hold regionally before ordering and got a straight list back. Changed what I ordered and when.

reflux at night, try not eating in the three hours before bed

nausea that arrives on day two and fades by day four is the standard shape

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

regional stock changes everything about transit

Disagree on this specific point.

Adding the bit that always gets missed: the lot on the vial has to match the lot on the page, or none of this applies to your material.

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

Yes. Holding the dose is a real option and it does not mean you have failed at anything.

Did protein intake change in the same window?

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.